Milestone Pharmaceuticals Stock Price, News & Analysis

Milestone Pharmaceuticals (Nasdaq: MIST) has announced a refresh of its Board of Directors. Stuart Duty and Andrew Saik have been appointed as new independent directors, effective immediately. A third independent director will be appointed in the near term. This move comes as part of a Cooperation Agreement with Alta Fundamental Advisers , a shareholder.

Mr. Duty brings over 30 years of experience in investment banking and operations in biotechnology and specialty pharmaceuticals. Mr. Saik has more than 25 years of accounting and finance experience, including CFO roles at several biopharmaceutical companies. The company expects their varied perspectives to provide valuable insights as Milestone approaches an exciting phase.

Debra K. Liebert and Richard C. Pasternak will not seek reelection at the upcoming Annual Meeting. The changes aim to strengthen leadership as Milestone works towards providing new treatment options for patients with paroxysmal supraventricular tachycardia and atrial fibrillation.

Milestone Pharmaceuticals (Nasdaq: MIST) will host Part I of its virtual investor educational series on June 20, 2024, at 8:00 AM ET. The event, titled “Learnings from the Field: Expert Perspectives on Managing PSVT in the Community Setting,” will feature Dr. George Mark and Dr. Vivek Sailam from The Heart House and Cooper University Health Care. They will discuss the impact of paroxysmal supraventricular tachycardia (PSVT) on patients, current treatments, unmet needs, and future treatment expectations. A live Q&A session will follow the presentation.

Milestone Pharmaceuticals (Nasdaq: MIST) announced its participation in the Jefferies Global Healthcare Conference in New York City from June 4-6, 2024. The company's management will engage in a Fireside Chat on June 6 at 11:30 AM EDT. The event will be webcast live and available for replay for about 90 days on Milestone's website.

Milestone Pharmaceuticals announced the FDA's acceptance of its New Drug Application for CARDAMYST, an etripamil nasal spray intended for managing paroxysmal supraventricular tachycardia (PSVT). This milestone occurred on May 26, 2024, with a Prescription Drug User Fee Act (PDUFA) target date set for ten months later. The clinical trial program for CARDAMYST is the largest data package studied for an acute drug treatment for PSVT self-management. Milestone is preparing for the anticipated launch of the product under the trade name CARDAMYST, which has conditional FDA approval.

Milestone Pharmaceuticals (Nasdaq: MIST) is partnering with Arrhythmia Alliance to raise awareness about supraventricular tachycardia (SVT). SVT Awareness Day is scheduled for June 5, 2024, during World Heart Rhythm Week (June 4-10). SVT affects two million people in the U.S., causing rapid heartbeats, breathlessness, and anxiety. The awareness campaign includes virtual coffee mornings, Live X Chat, and Facebook Live sessions with healthcare experts. Educational videos from patients and healthcare providers will also be released. The aim is to improve understanding and treatment of SVT, which often requires costly and invasive medical procedures.

Milestone Pharmaceuticals Inc. reported financial results for Q1 2024, resubmitted NDA for etripamil in PSVT, with expected FDA approval in the first half of 2025. The company's cash position is sufficient until 2026, with potential synthetic royalty payment. New clinical data for etripamil's real-world use were presented. Phase 3 guidance for etripamil in AFib-RVR was received from the FDA. Milestone closed a public offering, raising $32.2 million for development and commercialization. Financially, the company had $89.5 million in cash and no revenue in Q1 2024.

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced upcoming data presentations on etripamil at ISPOR 2024, the 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and Heart Rhythm 2024. The presentations will cover topics such as healthcare resource utilization in clinical trials and the effectiveness of etripamil nasal spray in termination of cardiac conditions.